Controlled Substances Act Clarification in Sciences Act of 2026
About This Bill
Committee
Latest Action · June 8, 2026
Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
This bill amends the Controlled Substances Act to update how the federal government classifies and regulates drugs by incorporating modern medical and scientific understanding. The legislation adds detailed definitions for key terms like "accepted medical use," "dependence liability," "abuse," and "misuse" to replace outdated language and reflect current medical practices. It also clarifies that the Attorney General must defer to the Secretary of Health and Human Services' scientific evaluation when deciding whether to add, remove, or reclassify drugs, and requires that scheduling decisions consider both potential harms and benefits to society while preserving legitimate medical access. The bill affects pharmaceutical companies, medical researchers, healthcare practitioners, and regulatory agencies like the FDA and DEA. No specific funding or implementation timeline is included in the text provided.
Take Action
Your position
Add a comment
to comment on this bill.
Annotate the text
Highlight any passage on the Summary or Full Text tab to attach a note. Annotations appear on the Annotations tab.